Advertisement

Neurosurgical Review

, Volume 20, Issue 4, pp 269–273 | Cite as

Sarcoidosis en-plaque. Report of a case and review of the literature

  • Erol Taşdemiroglu
  • Mohammed Nazek
  • Mario Zuccarello
Article

Abstract

A 31-year-old black male with sarcoidosis en-plaque of the dura mater, which is a rare morphological variant of neurosarcoidosis (NS), presented at our clinic. Magnetic resonance imaging (MRI) of the head with gadolinium showed non-specific enhancement of both tentorial leaves extending to the floor of right middle cranial fossa and cavernous sinus. The laboratory results were normal except for slightly increased serum angiotensin converting enzyme (SACE) (68 U/ml n = 4–56 U/ml) and cerebrospinal fluid (CSF) IgG index (0.57, n = 0.46). Biopsy of the intracranial dural lesion was consistent with sarcoidosis. Oral steroid therapy (Methylprednisolone 4 mg QID) was started and the patient became asymptomatic. However, MRI of the brain with gadolinium 2 months after biopsy showed progression and extension of the enhanced dural lesion. His SACE level was unchanged. We concluded that progression of the enhanced lesion seen in MRI could be recently formed scar tissue, new lesion or both. MRI findings should always be correlated with clinical findings for evaluation of NS during follow-up.

Keywords

Dura mater magnetic resonance imaging neurosarcoidosis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    Borucki SJ, BV Nguyen, CT Ladoulis, RR McKendall: Cerebrospinal fluid immunoglobulin abnormalities in neurosarcoidosis. Arch Neurol 46 (1989) 270–273PubMedGoogle Scholar
  2. [2]
    Cahill DW M Salcman: Neurosarcoidosis: Review of rarer manifestations. Surg Neurol 15 (1981) 204–212PubMedGoogle Scholar
  3. [3]
    Chapelon C, JM Ziza, JC Piette, Y Levy, G Raguin, B Wechsler, MO Bitker, O Bletry, D Laplane, MG Bousser, P Godeau: Neurosarcoidosis: Signs, course and treatment of 35 confirmed cases. Medicine 69 (1990) 261–276PubMedGoogle Scholar
  4. [4]
    Char G, EY St A Morrison, AJ Banbury: En-plaque subdural sarcoidosis. A rare neurologic entity. W Med J 37 (1988) 49–53Google Scholar
  5. [5]
    De Tribolet N, E Zander: Intracranial sarcoidosis presenting angiographically as a subdural hematoma. Surg Neurol 9 (1978) 169–171PubMedGoogle Scholar
  6. [6]
    Healton EB, G Zito, P Chauhan, JCM Brust: Intracranial subdural sarcoid granuloma. J Neurosurg 56 (1982)728–731PubMedGoogle Scholar
  7. [7]
    Heck AW, II LH Phillips: (1987) Neurologic Clinics 7 (1989) 641–654PubMedGoogle Scholar
  8. [8]
    Johns CJ, MI MacGregor, JB Zachary, WC Ball: Extended experience in the long-term corticosteroid treatment of pulmonary sarcoidosis. Ann NY Acad Sci 278 (1976) 722–731PubMedGoogle Scholar
  9. [9]
    Juozevicious JL, RI Rynes: Increased helper/suppressor T-lymphocyte ratio in the cerebrospinal fluid of a patient with neurosarcoidosis. Ann Int Med 104 (1986) 807–808PubMedGoogle Scholar
  10. [10]
    Luke R, BJ Stern, A Krumholz, CJ Johns: Neurosarcoidosis: The long-term clinical course. Neurology 37 (1987) 461–463PubMedGoogle Scholar
  11. [11]
    Matthews WB: Neurologic manifestations of Sarcoidosis. In:Asbury AK et al. (eds): Diseases of the Nervous System. Clinical Neurobiology. WB Saunders Company, Philadelphia, Vol 11, 1992Google Scholar
  12. [12]
    Mendez MF, B Zander: Frontal lobe dysfunction from meningeal sarcoidosis. Psychosomatics 33 (1992) 215–217PubMedGoogle Scholar
  13. [13]
    Michotte A, P Dequenne, D Jacobovitz, J Hildebrand: Focal neurological deficit with sudden onset as the first manifestation of sarcoidosis: A case report with MRI follow-up. Eur Neurol 31 (1991) 376–379PubMedGoogle Scholar
  14. [14]
    Oksanen V: Neurosarcoidosis: Clinical presentations and course in 50 patients. Acta Neurol Scand 73 (1986) 283–290PubMedGoogle Scholar
  15. [15]
    Osenbach RK, B Blumenkoph, H Ramirez, J Gutierrez: Meningeal neurosarcoidosis mimicking convexity en-plaque meningioma. Surg Neurol 26 (1986) 387–390PubMedGoogle Scholar
  16. [16]
    Ranoux D, B Devaux, C Lamy, JY Mear, FX Roux, JL Mas: Meningeal sarcoidosis, pseudo-meningioma, and pachymeningitis of the convexity. J Neurol Neurosurg Psych 55 (1992) 300–303Google Scholar
  17. [17]
    Seltzer S, AS Mark, SW Atlas: CNS sarcoidosis: Evaluation with contrast-enhanced MR imaging. AJNR 12 (1992) 1227–1233Google Scholar
  18. [18]
    Sethi KD, TE Gammal, BR Patel, TR Swift: Dural sarcoidosis presenting with transient neurological symptoms. Arch Neurol 43 (1986) 595–597PubMedGoogle Scholar
  19. [19]
    Sharma OP, AM Sharma: Sarcoidosis of the nervous system A clinical approach. Arch Int Med 151 (1986) 1317–1321Google Scholar
  20. [20]
    Sherman JL, BJ Stern: Sarcoidosis of the CNS: Comparison of unenhanced and enhanced MR images. AJNR 11 (1990) 915–923PubMedGoogle Scholar
  21. [21]
    Stern BJ, A Krumholz, C Johns, P Scott, J Nissim: Sarcoidosis and its neurological manifestations. Arch Neurol 42 (1985) 909–917PubMedGoogle Scholar
  22. [22]
    Studdy PR, R Bird: Serum angiotensin converting enzyme in sarcoidosis — is value in present clinical practice (Review article). Ann Clin Biochem 26 (1989) 13–18PubMedGoogle Scholar
  23. [23]
    Tibbling G, H Link, S Ohman: Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values. Scand J Clin Lab Invest 37 (1987) 385–390Google Scholar
  24. [24]
    Zimmerman RD, K Weingarten: Evaluation of in tracranial inflammatory disease by CT and MRI. In:Theodore WH (ed): Clinical Neuroimaging. Wiley, New York 1988Google Scholar

Copyright information

© Walter de Gruyter & Co. 1997

Authors and Affiliations

  • Erol Taşdemiroglu
    • 1
    • 2
  • Mohammed Nazek
    • 1
  • Mario Zuccarello
    • 1
  1. 1.Veterans Affairs Medical CenterNeurosurgical ServicesCincinnatiUSA
  2. 2.Incirli CaddesiIstanbulTurkey

Personalised recommendations